Copyright
©The Author(s) 2020.
World J Hepatol. Sep 27, 2020; 12(9): 628-640
Published online Sep 27, 2020. doi: 10.4254/wjh.v12.i9.628
Published online Sep 27, 2020. doi: 10.4254/wjh.v12.i9.628
Number (%) | |||
Characteristic | RBV-containing DAA regimens (n = 68) | Non-RBV containing DAA regimens (n = 38) | P value |
Age ≥ 60 yr | 38 (58) | 26 (70) | 0.2 |
Male | 51 (75) | 24 (63) | 0.3 |
Female | 17 (25) | 14 (37) | |
White | 37 (54) | 19 (50) | 0.8 |
Black | 15 (22) | 7 (18) | |
Hispanic | 13 (19) | 10 (26) | |
Asian | 3 (4) | 2 (5) | |
Diabetes Mellitus | 45 (66) | 28 (74) | 0.5 |
CKD | 22 (32) | 21 (55) | 0.02 |
eGFR < 30 mL/min/1.73 m2 | 1 (2) | 8 (21) | 0.001 |
Cirrhosis | 4 (8) | 5 (16) | 0.3 |
mean (± SD) creatinine level, mg/dL | 1.2 ± 1.0 | 1.9 ± 1.8 | 0.02 |
mean (± SD) hemoglobin level, g/dL | 14.0 ± 1.7 | 12.0 ± 2.0 | 0.0001 |
mean (± SD) MELD-Na score | 11 ± 4 | 13 ± 6 | 0.01 |
SVR12 | 65 (95.5) | 35 (92.1) | 0.7 |
- Citation: Ismail MS, Hassan M, Khaderi SA, Yousry WA, Kamal El-Din MM, Bahaa El-Din MM, El Sayed OA, Kaseb AO, Goss JA, Kanwal F, Jalal PK. Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma. World J Hepatol 2020; 12(9): 628-640
- URL: https://www.wjgnet.com/1948-5182/full/v12/i9/628.htm
- DOI: https://dx.doi.org/10.4254/wjh.v12.i9.628